30 JULY 2019
DEPT OF HEALTH, THERAPEUTIC GOODS ADMINISTRATION TGA:
Endone 5 mg tablets – Consumers & health professionals are advised that Aspen Pharma, is undertaking product defect correction for one batch of Endone 5 mg tablets
Consumers and health professionals are advised that Aspen Pharma, in consultation with the TGA, is undertaking a product defect correction for one batch of Endone 5 mg tablets (batch number CW612, expiry November 2020). A single pack of Endone 5 mg tablets in South Australia has been found to contain a blister sheet of Anamorph 30 mg tablets. While the product names were correctly printed on the back of the blister sheet, the tablets and the blisters are a similar size, shape and colour, which increases the risk of inadvertently taking the wrong medicine. Both Endone 5 mg tablets (containing oxycodone) and Anamorph 30 mg tablets (containing morphine) are strong, prescription pain medication. However, Anamorph 30 mg is a stronger dose (approximately four times the morphine equivalent dose of Endone) and could result in overdose and serious health risks if taken inadvertently.
